Executive Summary
Biventricular impairment before TAVR is the risk stratifier the field has been missing. A JACC Asia registry of 280 patients shows concurrent LV longitudinal and RV-PA coupling abnormalities carry a 5.7-fold adjusted 1-year risk of death or MACE, with event rates climbing from 7.1% in normal biventricular function to 53.2% when both ventricles fail. A propensity-matched TriNetX analysis of 55,147 TAVR patients separately shows SGLT2i initiation post-TAVR cuts the composite of death and HF exacerbation by 26% at 1 year, with a mortality signal emerging at 5 years. Together these findings sharpen a message the AS guidelines have circled but never landed: outcomes after valve replacement are as much about the ventricle as the valve, which tightens the case for earlier intervention before biventricular remodeling sets in.
- Concurrent LV/RV impairment quadruples 1-year post-TAVR event rates vs. isolated single-chamber dysfunction (53.2% vs. 19.3%) (JACC Asia).
- SGLT2i post-TAVR reduces HF exacerbation by 56% and rehospitalization by 59% at 1 year in matched cohorts (Critical Pathways in Cardiology).
- Single Perclose lowers arterial dissection risk vs. double (RR 0.32) with equivalent bleeding and mortality across 6,487 large-bore access cases (Cardiovasc Revasc Med).
- CMS opened a new National Coverage Analysis on TAVR (CAG-00430N), the first reconsideration of the 2019 NCD (CMS).
- Israeli single-center series reports 149 TAVIs performed at a non-surgical center with zero mortality and zero emergency conversions (Harefuah).
What to watch: The CMS NCA on TAVR coverage will dominate the next 60 days — the public comment period determines whether hospital volume thresholds, on-site surgery requirements, and the two-surgeon rule get loosened, tightened, or eliminated.
Aortic Valve (TAVR/TAVI)
The ventricle is the prognosis. A 280-patient TAVR registry in JACC Asia integrating LV global longitudinal strain with RV free-wall strain-to-PASP ratio produced four phenotypes with strikingly divergent outcomes: 7.1% event rate with no dysfunction, 19.3% with isolated LV impairment, 27.3% with isolated RV impairment, and 53.2% with both. Concurrent biventricular dysfunction carried an adjusted HR of 5.70 and pushed C-index from 0.731 to 0.771. Single-center, non-randomized, Asian cohort — external validation needed — but the signal aligns with what surgeons have argued for a decade: waiting until symptoms emerge means waiting until the ventricles remodel. The ESC 2025 shift toward earlier intervention (Class IIa) in asymptomatic severe AS reflects exactly this logic; the ACC/AHA 2020 watchful-waiting posture, which uses LVEF <50% as the primary trigger, misses subclinical strain-based dysfunction entirely.
Adjunctive medical therapy after TAVR is undertreated. A TriNetX matched analysis of 55,147 TAVR patients shows SGLT2i initiation post-TAVR reduces composite death/HF (HR 0.74) and rehospitalization (HR 0.41) at 1 year — an observational database study with confounding-by-indication risk, but a hard enough signal to warrant prospective evaluation. Neither the ACC/AHA 2020 nor ESC 2025 valve guidelines address post-TAVR SGLT2i use; this is a gap both guideline committees will need to close.
On the two-surgeon question, a Meir Medical Center series of 149 TAVIs without on-site cardiac surgery reports zero mortality and zero emergency conversions. Single-center and uncontrolled, but the data will feature prominently in the CMS NCA public comment period.
Mitral Valve (MitraClip, PASCAL, TMVR)
Coronary physiology and MR phenotype together predict TEER outcomes. A JACC Asia analysis stratifies mitral TEER outcomes by MR phenotype and coronary physiology — abstract-limited, but the accompanying editorial on shifting from anatomical to functional abnormalities frames the argument precisely: proportionate vs. disproportionate MR alone does not capture the ischemic burden driving ventricular SMR, and coronary FFR/iFR data should enter the TEER selection algorithm. The ESC 2025 upgrade of TEER to Class I for ventricular SMR used COAPT-style anatomic and hemodynamic criteria but does not require coronary physiology assessment — a meaningful omission given this data. The counterpoint cuts both ways: ACC/AHA 2020 and ESC 2025 both recommend MV surgery (ESC Class I; ACC/AHA Class IIa) when CAD requires concomitant CABG, and patients with unaddressed ischemia may be poor TEER candidates precisely because they are patients who should have been offered surgery.
A separate JACC Asia editorial on Chinese TEER innovation notes device iteration is expanding globally, but long-term durability data remain largely US/European.
Tricuspid Valve (TriClip, TTVR)
RV-PA coupling and pulmonary artery pressure — not TR grade — determine who benefits from tricuspid intervention. A contemporary TR review in Critical Pathways reinforces what recent STS/ACC TVT Registry data showed, and emphasizes device-related TR from CIED leads as an under-recognized driver where transcatheter options remain evidence-thin. ESC 2025 elevated TV surgery for symptomatic primary TR to Class I and placed transcatheter treatment at Class IIa for high-risk patients — but TRILUMINATE-eligible patients represent a narrow slice of the TR population. Patients with severe RV dysfunction or pre-capillary pulmonary hypertension remain outside the transcatheter envelope in both guidelines. The accompanying editorial on RV-PA uncoupling makes the necessary point: failing RV physiology is a continuum, and current treatment algorithms have not caught up to that reality.
Surgical vs. Transcatheter Comparisons
A commentary in the International Journal of Surgery makes a point that should stay in circulation: comparisons between TAVR and sutureless SAVR must account for device evolution and competing risks. Older TAVR devices in registry comparisons systematically underperform current-generation valves, and failure to censor for competing mortality inflates apparent transcatheter durability. This is the methodological ballast the field needs as ESC 2025 lowers the TAVI age threshold to 70 based on trials whose devices are already superseded. A related JACC Asia editorial ("When Does Valve Durability Matter?") puts the point plainly: durability matters most in patients with the longest life expectancy — precisely the group where RCT data are thinnest and where ACC/AHA 2020 still favors SAVR for patients under 65.
Device & Technology
A meta-analysis of 14 studies and 6,487 patients comparing single vs. double Perclose for large-bore transfemoral closure found equivalent technical success, bleeding, and 30-day mortality — but a 68% relative reduction in arterial dissection with the single-device strategy (RR 0.32, 95% CI 0.15-0.70). For centers running high TAVR volume, this challenges the default double-Perclose reflex. On imaging, a case report on CT-guided TAVR in bicuspid AS with a large membranous septal aneurysm illustrates why annular sizing algorithms need to accommodate anatomic outliers — virtual annular reconstruction excluding the aneurysm cavity delivered a successful 29mm Evolut FX+ deployment. Anecdotal, but instructive as bicuspid TAVR expands into anatomies that were surgical territory a decade ago; both ACC/AHA 2020 and ESC 2025 still rate TAVI for bicuspid AV at Class IIb, and NOTION 2 data showing a numerically higher event rate with TAVI in BAV patients remain the surgical counterweight. A JACC Asia study on intra-annular self-expandable device implantation and a JACC Asia commentary on AI-enabled ECG risk prediction before TAVR point to where the pre-procedural workup is heading: multimodal, individualized, and increasingly algorithmic.
Regulatory & Policy
[NOTABLE] CMS opened National Coverage Analysis CAG-00430N on TAVR, formally reconsidering the 2019 NCD. Three questions dominate: (1) Does the two-surgeon rule survive contemporary evidence of comparable outcomes at non-surgical centers, per the Meir Medical experience? (2) Do hospital volume thresholds — currently 50 TAVR/year to start, 20/year to maintain — get relaxed or tightened? (3) Does CMS align coverage with the ESC 2025 age-70 threshold, or hold to the ACC/AHA 2020 shared-decision zone for patients 65-80? The public comment period will draw sharp positions from STS and ACC. Expect Edwards and Medtronic to advocate for expanded access; expect surgical societies to hold the line on Heart Team and volume standards.
Industry & Market
The CMS NCA is the story that moves valuations for the next quarter. Any loosening of on-site surgery or volume requirements expands the addressable TAVR market by 15-25% into community hospitals — a direct tailwind for Edwards and Medtronic. Any tightening does the opposite. Boston Scientific's continued decline (down 34.5% over 6 months) is structural — post-Sentinel and post-Acurate slowdowns compound the loss of the AS growth narrative — and the CMS NCA does not directly help or hurt them. Anteris continues to trade on DurAVR pipeline momentum, up 32% over 6 months on modest volume.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $90.82, +0.09% on the day, +6.5% over 6 months
- Market cap $52.3B; trailing P/E 54.06; forward P/E 26.89; beta 0.85
- 52-week range $72.30 – $96.29
- Analyst target $100.96 (range $84–$110, 26 analysts); consensus Buy
- Next earnings 10/29/2026: EPS est $0.74, revenue est $1.68B
Edwards has recovered from the 2024 SAPIEN-growth scare and trades near 52-week highs. EARLY TAVR data underpinning ESC 2025's asymptomatic AS recommendation is the durable tailwind. The CMS NCA is the near-term catalyst.
Medtronic (MDT)
- Close: $92.18, +0.15% on the day, -3.0% over 6 months
- Market cap $118.0B; trailing P/E 24.71; forward P/E 14.41; beta 0.57
- 52-week range $73.31 – $106.33
- Analyst target $102.88 (range $78–$121, 25 analysts); consensus Buy
- Next earnings 11/17/2026: EPS est $1.33, revenue est $9.48B
Evolut FX+ is winning share in complex anatomies — today's bicuspid AS case report is a small data point in a broader trend. The CMS NCA benefits Medtronic symmetrically with Edwards.
Abbott (ABT)
- Close: $110.47, +1.41% on the day, -1.5% over 6 months
- Market cap $191.2B; trailing P/E 35.75; forward P/E 18.21; beta 0.58
- 52-week range $81.97 – $137.49
- Analyst target $120.20 (range $103–$135, 25 analysts); consensus Buy
- Next earnings 10/14/2026: EPS est $1.42, revenue est $12.99B
MitraClip and TriClip remain the structural heart franchise. The ESC 2025 upgrade of TEER for ventricular SMR to Class I is a multi-year tailwind; today's coronary physiology data will influence patient selection but not overall volume.
Boston Scientific (BSX)
- Close: $48.37, +0.60% on the day, -34.5% over 6 months
- Market cap $70.1B; trailing P/E 19.43; forward P/E 14.09; beta 0.57
- 52-week range $42.20 – $109.50
- Analyst target $62.69 (range $44–$94, 29 analysts); consensus Buy
- Next earnings 10/28/2026: EPS est $0.81, revenue est $5.26B
The 6-month decline reflects concerns beyond valves — WATCHMAN growth deceleration and EP competition — but the Acurate withdrawal from the US market removed a structural heart growth vector. The $62.69 analyst target implies material recovery expected.
Anteris Technologies (AVR.AX)
- Close: A$11.94, +1.62% on the day, +32% over 6 months
- Market cap A$1.2B; forward P/E -5.51; 52-week range A$5.20 – A$15.47
- Single analyst target A$13.00
DurAVR pivotal enrollment and the single-piece valve narrative continue to drive momentum. Speculative — no commercial revenue, and the TAVR durability question is exactly what pre-commercial single-piece valves need to prove.
Market outlook: The structural heart sector trades on two things right now — the CMS NCA and long-term TAVR durability. Today's biventricular dysfunction data reinforce the "intervene earlier" thesis that underpins Edwards and Medtronic's growth stories. The Boston Scientific weakness is idiosyncratic, not sector-wide.
Clinical Trial Updates
No new randomized trial readouts today. Ongoing trials to watch: EARLY TAVR long-term follow-up, PROGRESS (moderate AS with HFrEF, following today's negative signal in an earlier readout), and NCT05051033 comparing TEER vs. surgery for primary MR in patients >60. The CMS NCA public comment period will surface additional real-world data submissions from high-volume programs.
The through-line: valve intervention outcomes are ventricular outcomes, and both the transcatheter and surgical fields are converging on earlier intervention before ventricular damage becomes irreversible. The CMS NCA over the next 60 days will determine how quickly that earlier-intervention paradigm reaches community hospitals — and whether the two-surgeon rule survives the contemporary evidence.